Rebound phenomenon of proton pump inhibitors therapy
Abstract
Proton pump inhibitors (PPIs) are the most potent drugs for suppressing gastic acid secterion. They are used in the treatment of acid-peptic disorders, including peptic ulcer disease, gastroesophageal reflux disease, Zollinger Ellison syndrome, in the eradication of Helicobacter pylori infection, and ulcer prophylaxis. In the pharmacotherapy of these disorders, they have significantly suppressed the use of H2 blockers, like other, older groups of antisecretory drugs.
Long-term PPI therapy leads to moderate hypergastrinemia (increased gastrin secretion) in 20-25% of patients. This hypergastrinemia results in rebound acid hypersecretion (RAHS) in 30-40% patients, who abruptly discontinue PPI. Most patients who abruptly discontinue PPI have symptoms of dyspepsia and gastroesophageal reflux, most commonly heartburn and a burning sensation in the esophagus.
Therefore, care should be taken to properly discontinue PPI and reduce the dose of the drug before complete discontinuation. A less effective acid blocker (H2 blocker) can be switched, since H2 receptor blockers cause less pronounced hypergastrinemia and hyperplasia of enterochromaffin-like cells (ECL cells) compared to PPI.
References
Bloom SR, Mortimer CH, Thorner MO, Besser GM, Hall R, Gomez-Pan A, et al. Inhibition of gastrin and gastric-acid secretion by growth-hormone release-inhibiting hormone. Lancet 1974;2:1106-9. [CrossRef] [PubMed]
Brusselaers N, Wahlin K, Engstrand L, Lagergren J. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: A nationwide population-based cohort study in Sweden. BMJ Open 2017;7, e017739. [CrossRef] [PubMed]
Cavalcoli F, Zilli A, Conte D, Ciafardini C, Massironi S. Gastric neuroendocrine neoplasms and proton pump inhibitors: Fact or coincidence? Scand J Gastroenterol 2015;50:1397-1403. [CrossRef] [PubMed]
Cheung KS, Chan EW, Wong AYS, Chen L, Wong ICK, Leung WK. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: A population-based study. Gut 2018;67:28-35. [CrossRef] [PubMed]
Chu S, Schubert ML. Gastric secretion. Curr Opin Gastroenterol 2013;29:636-41. [CrossRef] [PubMed]
Gedda K, Scott D, Besancon M, Lorentzon P, Sachs G. Turnover of the gastric H+,K(+)-adenosine triphos-phatase alpha subunit and its effect on inhibition of rat gastric acid secretion. Gastroenterology 1995;109: 1134-41. [CrossRef] [PubMed]
Halfdanarson OO, Pottegard A, Bjornsson ES, Lund SH, Ogmundsdottir MH, Steingrimsson E, et al. Pro-ton-pump inhibitors among adults: A nationwide drug-utilization study. Therap Adv Gastroenterol 2018;11: 1-11. [CrossRef] [PubMed]
Hatlebakk JG, Katz PO, Camacho-Lobato L, Castell DO. Proton pump inhibitors: Better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther 2000; 14: 1267–1272. [CrossRef][PubMed]
Helgadottir H, Lund SH, Gizurarson S, Metz DC, Bjornsson ES. Predictors of Gastrin Elevation Following Proton Pump Inhibitor Therapy. J Clin Gastroenterol 2020;54:227-34. [CrossRef] [PubMed]
Helgadottir H, Metz DC, Lund SH, Gizurarson S, Jacobsen EI, Asgeirsdottir GA, et al. Study of Gender Dierences in Proton Pump Inhibitor Dose Require-ments for GERD: A Double-Blind Randomized Trial. J Clin Gastroenterol 2017;51:486-93. [CrossRef] [PubMed]
Katz PO, Gerson LB, Vela MF. Guidelines for the diag-nosis and management of gastroesophageal reflux disease. Am J Gastroenterol 2013;108:308-28. [CrossRef] [PubMed]
Koraćević M, Lalić J, Nedeljković S, Koraćević G. Rebound phenomenon-important and ubiquitous in pharmacotherapy. Acta Medica Medianae 2018;57: 148-52. [CrossRef]
Lundell L, Vieth M, Gibson F, Nagy P, Kahrilas PJ. Systematic review: The effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Aliment Pharmacol Ther 2015;42:649-63. [CrossRef] [PubMed]
Pasina L, Urru SA, Mandelli S, Giua C, Minghetti P. Evidence-based and unlicensed indications for proton pump inhibitors and patients' preferences for disconti-nuation: a pilot study in a sample of Italian commu-nity pharmacies. J Clin Pharm Ther 2016;41:220-223. [CrossRef] [PubMed]
Rašić J, Rašić D, Janićijević Hudomal S, Nestorović V. Inhibitori protonske pumpe-primena i bezbednost. Biomedicinska istraživanja 2013;4: 48-56. [CrossRef]
Reimer C, Bytzer P. Clinical trial: Long-term use of proton pump inhibitors in primary care patients-A cross sectional analysis of 901 patients. Aliment Pharmacol Ther 2009;30:725-32. [CrossRef] [PubMed]
Shin JM, Kim N. Pharmacokinetics and pharmacodyna-mics of the proton pump inhibitors. J Neurogastro-enterol Motil 2013;19:25-35. [CrossRef] [PubMed]
Strand DS, Kim D, Peura DA. 25 Years of Proton Pump Inhibitors: A Comprehensive Review. Gut Liver 2017; 11: 27-37. [CrossRef [PubMed]
Tran-Duy A, Spaetgens B, Hoes AW, deWit NJ, Stehouwer CD. Use of Proton Pump Inhibitors and Risks of Fundic Gland Polyps and Gastric Cancer: Systematic Review and Meta-analysis. Clin Gastro-enterol Hepatol 2016;14:1706-19. [CrossRef] [PubMed]
Waldum HL, Hauso O, Brenna E, Qvigstad G, Fossmark R. Does long-term profound inhibition of gastric acid secretion increase the risk of ECL cell-derived tumors in man? Scand J Gastroenterol 2016; 51:767-73. [CrossRef] [PubMed]
Waldum HL, Qvigstad G, Fossmark R, Kleveland PM, Sandvik AK. Rebound acid hypersecretion from a physiological, pathophysiological and clinical view-point. Scand J Gastroenterol 2010;45:389-94. [CrossRef] [PubMed]
Zwisler JE, Jarbol DE, Lassen AT, Kragstrup J, Thorsgaard N, Schaffalitzky de Muckadell OB. Placebo-Controlled Discontinuation of Long-Term Acid-Sup-pressant Therapy: A Randomised Trial in General Practice. Int J Fam Med 2015;175436. [CrossRef] [PubMed]